Company Frazier Lifesciences Acquisition Corporation

Equities

NAMS

NL00150012L7

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for Frazier Lifesciences Acquisition Corporation

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

FRAZIER LIFESCIENCES ACQUISITION CORPORATION

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
19.81 ^EUR	-3.37%		-7.56%	+77.35%

May. 15	TD Cowen Starts NewAmsterdam Pharma With Buy Rating	MT
May. 09	Earnings Flash (NAMS) NEWAMSTERDAM PHARMA N.V. Reports Q1 Revenue $1.4M	MT

NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimerâs disease. The Company strives to offer its products around the world.

Number of employees: 29

USD in Million	2022	Weight	2023	Weight	Delta
Transformative Therapies for Cardio-metabolic Diseases 100.0 %	102	100.0 %	15	100.0 %	-85.13%

USD in Million	2022	Weight	2023	Weight	Delta
Italy 100.0 %	102	100.0 %	15	100.0 %	-85.13%

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	89,976,538	84,821,998 ( 94.27 %)	0	94.27 %

Name	Equities	%	Valuation
Frazier Life Sciences Management LP 13.70 %	12,226,943	13.70 %	262 M €
Forbion Capital Partners Management Holding BV 13.25 %	11,831,461	13.25 %	254 M €
Bain Capital Life Sciences LP 11.73 %	10,473,913	11.73 %	225 M €
Viking Global Investors LP 8.989 %	8,024,565	8.989 %	172 M €
RA Capital Management LP 8.810 %	7,864,000	8.810 %	169 M €
AMGEN INC. 5.500 %	4,910,000	5.500 %	105 M €
Morningside Group Ltd. 4.549 %	4,060,923	4.549 %	87 M €
Medicxi Ventures (Jersey) Ltd. 3.215 %	2,869,565	3.215 %	62 M €
Adage Capital Partners GP LLC 2.044 %	1,824,601	2.044 %	39 M €
BVF, Inc. 1.705 %	1,521,948	1.705 %	33 M €

Name	Equities	%	Valuation
Frazier Life Sciences Management LP -	500,333	-	5 M €
RA Capital Management LP -	333,333	-	3 M €
Affinity Asset Advisors LLC -	202,599	-	2 M €
GTS Securities LLC -	121,150	-	1 M €
Bain Capital Life Sciences LP -	100,000	-	963 000 €
Deerfield Management Co. LP (Private Equity) -	92,787	-	893 539 €
Monashee Investment Management LLC -	31,189	-	300 350 €
HRT Financial LLC -	30,321	-	291 991 €
Laurion Capital Management LP -	16,666	-	160 494 €
Vestcor, Inc. -	9,632	-	92 756 €

NewAmsterdam Pharma Co. NV

Gooimeer 2-35

1411 DC, Naarden

+31 35 206 2971

http://www.newamsterdampharma.com

address Frazier Lifesciences Acquisition Corporation(NAMS)

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

18.48 EUR

Average target price

32.11 EUR

Spread / Average Target

+73.77%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
FRAZIER LIFESCIENCES ACQUISITION CORPORATION	+77.35%	1.81B
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
BIONTECH SE	-14.15%	21.84B
ARGENX SE	-1.05%	21.96B
GENMAB A/S	-5.29%	19.21B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
BEIGENE, LTD.	-4.16%	18.08B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs